newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

  • Tvardi Therapeutics management will present at Chardan's 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM ET.
  • Registered investors attending the conference will have the opportunity to meet with the Tvardi management team.
  • Tvardi is a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 for inflammatory & proliferative diseases.
  • The company completed a Phase 1 healthy volunteer study of TTI-109 & plans to initiate GI disease clinical trials pending IND clearance & additional funding.
  • Tvardi is currently conducting a Phase 1b/2 clinical trial of TTI-101 for hepatocellular carcinoma (NCT05440708).